An experienced team that has completed similar product ventures from conception to commercialization through internal sales and marketing and/or major strategic partnerships. The key executives have a track record of successfully developing and marketing high volume products in the healthcare field. As a result, PRED will be able to benefit from and leverage valuable relationships with industry leaders. Discussions have already commenced with significant companies that have major women’s health franchises.
President & CEO
Previously President, Sagent Technologies (medical device division of Sagent Pharmaceuticals), CEO/Co-Founder of Infusive Technologies (developer of drug delivery technologies) and Director/Co-Founder of Specialized Health Products, Inc., acquired by C.R. Bard, Inc. Mr. Robinson studied accounting at the University of Utah and received a Masters of International Management from the Thunderbird, The American Graduate School of International Management.
Michael Dey, Ph.D. is a member of the Board of Directors of Predictive Technology Group, Inc. Dr. Dey will assist in corporate governance and guide the development and commercialization of technology and products in all PRED’s subsidiaries.
In addition to serving as a PRED Board Member, Dr. Dey will continue as Chief Executive Officer of Predicitive Therapeutics, Inc., a wholly owned subsidiary of PRED. Before joining PRED, Dr. Dey had executive positions at Wyeth, later acquired by Pfizer, where he was both the President and the President of Scientific Affairs division for Wyeth’s Women’s Health Care business. As President of Wyeth’s Women’s Health Care business for seven years, Dr. Dey managed its global resources of more than $3 billion annually.
Dr. Dey received an undergraduate degree in Biology/Chemistry in 1973, a Master’s Degree in 1980 in Pharmacology and Toxicology and a Ph.D. in 1984 in Pharmacology and Toxicology
Chairs Scientific Advisory Board- Predictive Therapeutics, Inc.
John E. Sorrentino chairs the Predictive Therapeutics’ Scientific Advisory Board. Predictive Therapeutics, a wholly owned subsidiary of Predictive Technology Group, Inc., specializes in genetic testing, diagnostics, and therapeutic products to advance precision medicine. Sorrentino is Vice-President and Chief Operating Officer of Vaccine Research and Development at Pfizer and brings his vast experience in R&D and clinical laboratory management to the Predictive Therapeutics’ Advisory team.
Sorrentino has over 35 years of senior management experience in the life sciences. Focused on improving public health, he has held leadership roles in private, and public companies, as well as government and non-profit institutions. Prior to joining Wyeth, later acquired by Pfizer, 14 years ago, Sorrentino held executive positions in several organizations that provided neonatal screening and related clinical services. Sorrentino’s expertise has had him appear before state legislators, the US Congress and professional societies on a variety of healthcare and policy issues.
Mr. Sorrentino experiences in clinical testing and women’s health will be an invaluable addition to the Company’s current team of experts and its mission to effectively treat endometriosis
Scientific Advisory Board
Dr. Taylor, a Chief of Obstetrics and Gynecology at Yale University, brings extensive clinical research and development expertise in endometriosis and women’s health to PRED’s Scientific Advisory Board team.
Dr. Taylor’s many accomplishments include Anita O’Keeffe Young Professor and Chairs Department of Obstetrics Gynecology and Reproductive Sciences at Yale School of Medicine and Chief of Obstetrics, and Gynecology at Yale-New Haven Hospital. He teaches as Professor of Molecular, Cellular and Developmental Biology at Yale University. His clinical interests include endometriosis, infertility, implantation, Asherman’s syndrome, menopause and uterine anomalies
.Also, Dr. Taylor, a board-certified specialist in Obstetrics and Gynecology and in Reproductive Endocrinology, received eight National Institutes of Health research grants. Dr. Taylor published more than 300 articles in leading medical journals, continues as the Editor-In-Chief of Reproductive Sciences, and elected to the membership of the National Academy of Medicine.
Dr. Taylor received his undergraduate training at Yale University and his medical degree from the University Of Connecticut School Of Medicine. He completed his residency in obstetrics and gynecology at Yale. His postdoctoral training included a fellowship in reproductive endocrinology and infertility, as well as, a fellowship in molecular biology, both at Yale.
Scientific Advisory Board
Dr. Nelson an obstetrician and gynecologist from Salt Lake City, Utah, brings a wealth of experience to PRED. Predictive Technology Group, Inc., specializes in genetic testing, diagnostics, and therapeutic products to advance precision medicine.
Dr. Nelson served as President of the American Medical Association, Salt Lake County Medical Society, and the Utah Medical Association. Also, he chaired the Finance and Planning Committee of the World Medical Association. He served on the Advisory Committee to the Director of the National Institutes of Health (NIH), as well as, on the advisory committee for the Agency for Healthcare Research and Quality (AHRQ). As a spokesperson for the American Medical Association Alliance, he lectured on detecting and preventing interpersonal violence. Dr. Nelson became a charter member of the Prospective Payment Assessment Commission (ProPAC), now known as MedPAC.
Dr. Nelson received numerous awards, among which are the Alumnus of the Year at Utah State University, the Distinguished Service Award from the University of Utah School of Medicine, the Emeritus Merit of Honor Award from the University of Utah Alumni Association, and the Light of Learning Award from the Utah Department of Education. As a founding co-chair of the Commission to End Healthcare Disparities, Dr. Nelson received a Lifetime Service Award from the National Medical Association.
Dr. Nelson’s civic involvement includes time on the advisory committee of the local Boys and Girls Club of Salt Lake City, the Christmas Box House board, and the board of Operation Kids.
Financial Advisory Board Member / Scientific Advisory Board
Dr. Prince pioneered the prevention of the respiratory syncytial virus (RSV) disease in high-risk infants through the use of monoclonal antibody (Synagis®. is currently marketed through a partnership between MedImmune and Abbvie).
Dr. Prince brings pharmaceutical research and development and commercialization expertise to the Scientific Advisory Board team.
After earning doctorate degrees at UCLA (DDS, 1973; PhD, 1975) and serving a post-doctoral fellowship at the National Institutes of Health, Dr. Prince spent four decades in virology research, with a focus on the respiratory syncytial virus (RSV). He pioneered the prevention of RSV disease in high-risk infants, and as co-founder and CEO of Virion Systems, Inc. worked with MedImmune (acquired by AstraZeneca in 2007) to develop Synagis®. AstraZeneca markets Synagis within the United States, while AbbVie markets Synagis in all other regions.
Dixie State University-St. George, Utah inducted Dr. Prince to its Hall of Fame in 1999, in recognition of his scientific achievements, and later in 2012, the university granted him an honorary Doctorate of Humanities. Dr. Prince serves on the national advisory councils at four universities, and as the governor of Wesley Theological Seminary in Washington, D.C. He holds adjunct professorships at UCLA and Dixie State University and currently serves as Chief Scientific Officer at Soft Cell Biological Research, LLC. National Advisory Councils, Johns Hopkins University School of Education, Utah Valley University, Dixie State University (chair); author of over 150 scientific publications in the field of infectious diseases.
Vice President of Business Development
Over 25 years of experience in strategic sales and business development consultancy in both foreign and domestic markets. Mr. Turner worked as a business development consultant for Griffin Financial. He was a co founder and managing partner of JMGS in Brazil, a financial advisory firm that provided investment banking services and asset management for clients entering Brazilian markets. He is also strategic sales consultant for American Health Systems, in which he structured the monetization of its medical diagnostic technology and bolstered its sales force with over 100 active medical sales reps. Mr. Turner’s lifetime experience in strategic business development, finance and personal network within the healthcare space, has been an invaluable asset to PRED.
Financial Advisory Board Member
Managing Director, JC Capital. He was previously Managing Director, Head of European Equity Derivatives, and Head of Northern Europe, Barclays Capital, London, Managing Director and Head of Nordics, Credit Suisse, London and Vice President, Bankers Trust. Previous Board Member of Enter Card Europe.
Financial Advisory Board Member
Retired President and CEO of ING Financial Advisers, LLC, Systematized Benefits Administrators, Inc., and ING Investment Advisors, LLC. Mr. Barhorst served as a director of ING Life Insurance Holding Company, Inc. and as an officer of several other ING companies. Mr. Barhorst currently serves as Chairman on the California State University Foundation Board of Governors.
Chairman and CEO at Juneau Biosciences. Board certification in Obstetrics and Gynecology, Maternal Fetal Medicine, Molecular Genetics and Medical Genetics.
Chief Sales Officer
Partner, FlagShipSales. Previously VP Sales and Operations at Walgreens and National VP of Self-Funded Sales at UnitedHealth Group.
Chief Marketing Officer
Partner, FlagShipSales and Chief Marketing Officer.